Company intelligence / Profile preview

Sharpview Ophthalmology

London, Greater London, United Kingdom

Ownership: Private
Employees: ~5
Development stage: Other

Overview

Clinical studies in over 113 eyes with intermediate-severe AMD show improved visual acuity (mean gain ≥1 line CDVA in 95% of patients, 3-line gain in 35%). Benefits persist for up to 9 years post-implant. The technology is considered a major advance for AMD patients, improving vision area and quality beyond standard IOLs

Therapeutic areas: Ophthalmology
Modalities: Device
Industry: Implantable Medical Devices

Partnerships

Visure Ophthalmics Ltd (major shareholder, 51%)Syneos Health Commercial Europe Limited (49%)

Beyond the preview

Go deeper on Sharpview Ophthalmology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sharpview Ophthalmology.

Explore the full profile